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Background. Reliable reverse transcription polymerase chain reaction (RT-PCR)–based diagnosis of Ebola virus
infection currently requires a blood sample obtained by intravenous puncture. During the current Ebola outbreak in
Guinea, we evaluated the usability of capillary blood samples collected from ﬁngersticks of patients suspected of
having Ebola virus disease (EVD) for ﬁeld diagnostics during an outbreak emergency.
Methods. A total of 120 venous and capillary blood samples were collected from 53 patients admitted to the
Ebola Treatment Centre in Guéckédou, Guinea, between July and August 2014. All sample specimens were analyzed
by RT-PCR using the RealStar Filovirus Screen RT-PCR Kit 1.0 from altona Diagnostics (Germany). We compared
samples obtained by venipuncture and those obtained by capillary blood sampling absorbed onto swab devices.
Results. The resulting sensitivity and speciﬁcity of tests performed with capillary blood samples were 86.8% (95%
conﬁdence interval [CI], 71.9%–95.6%; 33/38 patients) and 100% (95% CI, 84.6%–100%; 22/22 patients), respectively.
Conclusions. Our data suggest that capillary blood samples could serve as an alternative to venous blood samples
for the diagnosis of EVD in resource-limited settings during a crisis. This can be of particular advantage in cases when
venipuncture is difﬁcult to perform—for example, with newborns and infants or when adult patients reject venipunc-
ture for cultural or religious reasons.
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The current Ebola virus outbreak inWest Africa was ﬁrst
described in March 2014 in Guinea [1]. Since then, Ebola
has widely spread to the neighboring countries of Liberia
and Sierra Leone. Although intense and widespread
transmission of the current Ebola outbreak has been
limited to these 3 countries, cases were also reported
in Mali, Nigeria, and Senegal as well as in Europe and
the United States [2, 3].As of 11 March 2015, the World
Health Organization (WHO) reported a total of 24 282
cases of Ebola virus disease (EVD) with 9976 deaths [4],
making the ongoing outbreak in West Africa by far the
geographically most widespread and most complex
Ebola outbreak since Ebola virus was ﬁrst discovered
in 1976 [5]. Reported EVD case fatality rates vary
from 31% to 74% in the main affected West African
countries [6–11].
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Effective outbreak containment measures include the strict
isolation of EVD patients, which requires reliable diagnosis.
Current methods to diagnose suspected Ebola virus infection
include reverse transcription polymerase chain reaction (RT-
PCR), antigen-capture enzyme-linked immunosorbent assay
(ELISA), and immunoglobulin M (IgM) and immunoglobulin
G (IgG) ELISA [12–19]. While detection of viral RNA or viral
antigen has been proven effective for diagnosis of Ebola virus
infections from the early until late stage of illness, serological
detection of speciﬁc IgM and IgG antibodies can only be used
for diagnosis of EVD at the late stage in the acute phase of the
disease and during convalescence.
All current techniques for the reliable laboratory diagnosis of
Ebola virus infection require whole blood, plasma, or serum col-
lected by venipuncture. In addition, the use of oral ﬂuid speci-
mens has been suggested as a noninvasive, sensitive method for
the detection of Ebola virus infections during outbreak investi-
gations [20].
Venous blood sampling requires trained and skilled medical
personnel, bears high risk for needlestick injuries, and is espe-
cially difﬁcult to perform with newborns and infants. Moreover,
patients in African settings often refuse venipuncture due to
cultural and religious beliefs. To overcome these problems, we
evaluated the suitability of capillary blood sampling from ﬁn-
gersticks in the diagnosis of EVD. The main objective of this
study was to compare the sensitivity and speciﬁcity of tests
that used capillary blood samples with samples obtained by ve-
nous puncture during an outbreak emergency. Furthermore, we
assessed in a limited study the stability of capillary blood swab
samples when stored at room temperature vs 4°C.
MATERIALS AND METHODS
Ethical Approval
The National Committee of Ethics in Medical Research of Guinea
approved the use of diagnostic leftover samples for this study (per-
mit number 11/CNERS/14). As the samples had been collected as
part of the public health response to contain the outbreak in
Guinea, informed consent was not obtained from patients.
Sample Collection
The study was conducted during the current outbreak of EVD in
Guinea between July and August 2014. The study included 53 pa-
tients presenting with symptoms compatible with the WHO case
deﬁnition for EVD [21]. Clinical samples were collected by Mé-
decins sans Frontières (MSF) medical health personnel at the
Ebola Treatment Centre (ETC) in Guéckédou, Guinea, wearing
personal protective equipment following MSF safety guidelines.
For each patient, whole blood obtained by venipuncture and
capillary blood samples taken from ﬁngersticks were collected
at the same time. Venipuncture whole blood samples were
collected using 6.0 mL BD Vacutainer collection tubes contain-
ing ethylenediaminetetraacetic acid (EDTA) (Becton Dickin-
son, East Rutherford, New Jersey). Capillary whole blood
samples were collected from ﬁngerpricks using BD Microtainer
contact activated lancets, type 21G (Becton Dickinson, East
Rutherford, New Jersey). Collected capillary blood was ad-
sorbed on viscose swab collection applicators (Sarstedt, Germa-
ny) and immediately placed into a labeled sterile collection tube
without viral transport medium. Samples were stored at room
temperature (the mean temperature in Guéckédou is 23.8°C
in July and August) until they were transferred to the laboratory
for analysis. All samples were packaged with a triple packaging
system following WHO safety recommendations for sample
shipment. All sample tubes, plastic containers, and sealed plas-
tic bags used for transport were surface disinfected with a 0.5%
hypochlorite solution, and transported to the European Mobile
Laboratory in Guéckédou, where they arrived on average within
1 hour after collection. Matching venipuncture blood sample
and ﬁngerstick sample specimen from the same patient were la-
beled with the same unique laboratory identiﬁcation number
and an additional mark for capillary blood samples. All sample
specimens were subjected to the same handling and storage
conditions. One hundred twenty venous and capillary blood
samples from 53 patients with suspected EVD were obtained.
Laboratory Tests
Infectious sample specimens were handled in the European Mo-
bile Laboratory in Guéckédou, Guinea, by qualiﬁed and trained
laboratory personnel using a mobile safety glovebox cabinet,
equipped with P3 and ABC ﬁlters and operated with negative
pressure. All venous blood samples and capillary blood samples
were examined for detection of Ebola virus RNA by RT-PCR
using RealStar Filovirus Screen RT-PCR Kit 1.0 (altona Diagnos-
tics, Germany) [22], speciﬁcally targeting the L gene as described
previously [15]. Negative and positive controls were included in
every batch of samples analyzed. To ensure the integrity of Ebola
virus–speciﬁc real-time RT-PCR results by indicating potential
RT-PCR inhibition, an internal control was analyzed in parallel
for each patient sample. RT-PCR was performed using the
SmartCycler technology (Cepheid). To this end, aliquots (140
µL) from each sample were inactivated by adding 560 µL of the
guanidine thiocyanate lysis buffer AVL. Following 10 minutes of
incubation, 560 µL of absolute ethanol was added to the aliquots.
All sample tubes were surface disinfected using 0.5% hypochlo-
rite solution for 5 minutes prior to release from the glovebox. For
RT-PCR analysis of venipuncture blood samples, 50 µL of EDTA
whole blood (plus 90 µL of nuclease-free water; Qiagen, Germa-
ny) or 140 µL plasma was used for RNA extraction using the
QIAmp Viral RNA kit (Qiagen, Germany).
Plasma was obtained by centrifugation of EDTAwhole blood
at 3500 rpm for 10 minutes. Comparison of Ebola viral loads
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using RT-PCR in 50 µL of EDTAwhole blood or 140 µL plasma
revealed similar results (unpublished ﬁeld data). Swabs were
swirled in 300 µL of nuclease-free water (Qiagen, Germany)
in a 1.5-mL Eppendorf tube to redissolve biological material,
and 140 µL of supernatant was used for RNA extraction with
the QIAmp Viral RNA kit. Extraction and puriﬁcation of
RNA from venous and capillary blood samples was done ac-
cording to the manufacturer’s instructions with an additional
second wash step using AW2 buffer. For differential diagnosis,
admitted patients in the ETC were tested for malaria infections
using venous EDTAwhole blood for the qualitative detection of
Plasmodium species antigens in a commercially available in
vitro immunochromatographic assay using BinaxNOWMalaria
(Alere).
Statistical Analysis
To determine sensitivity and speciﬁcity of the capillary blood
sample tests, RT-PCR results were compared to those obtained
with venous blood samples. Sensitivity and speciﬁcity of the
tests were calculated using a 2-by-2 contingency table.
RESULTS
During the Ebola outbreak in Guinea, 53 Guinean patients
presenting with clinical symptoms of EVD were included in
the study. Among the 53 patients, 18 (33.9%) were men and
35 (66.1%) were women. The mean age was 27.4 years (range,
1–80 years). Venous and capillary blood samples were collected
simultaneously from each patient and analyzed for the presence
of Ebola virus RNA by real-time RT-PCR. Of the 60 capillary
blood samples analyzed, 33 tested positive and 27 negative for
EVD. For the 60 corresponding venous blood samples, 38 tested
positive and 22 negative for EVD. Identical results between cap-
illary and venous samples were observed for 55 samples, while 5
samples revealed false-negative results using capillary blood sam-
ples. For the 55 capillary blood samples with identical results, 33
tested EVD positive and 22 tested EVD negative. In our study, no
false-positive results were observed using capillary blood samples
as a diagnostic specimen. The sensitivity and the speciﬁcity of
tests performed with capillary blood samples absorbed onto
swab devices compared to tests performed with venous blood
samples were 86.8% (95% conﬁdence interval [CI], 71.9%–
95.6%; 33/38 patients) and 100% (95% CI, 84.6%–100%; 22/22
patients), respectively (Table 1). Table 2 summarizes the compar-
ative analysis of RT-PCR–based EVD detection in venous blood
and capillary blood samples according to the time of sampling
after onset of clinical symptoms. With the exception of 1 sample
pair, pairwise comparison of venous and corresponding capillary
blood samples revealed lower levels of Ebola RNA in capillary
blood samples, regardless of the time to sampling after symptom
onset. False-negative RT-PCR results caused by RT-PCR
inhibition have been reported for patients with viral hemorrhagic
fevers [23]. However, analysis of cycle threshold (Ct) values for
the corresponding internal control for each individual patient
sample indicated that a higher Ct value or even a negative RT-
PCR result for Ebola virus–speciﬁc RNA in capillary blood sam-
ples was not due to severe RT-PCR inhibition (Supplementary
Tables 1 and 2, Supplementary Figure 1).
The discrepancy in Ct values may stem from differences in re-
covery efﬁciency of viral RNA between both sample specimen
types. Alternatively, differences in viral load levels in capillary
and venous blood may account for the observed Ct variations,
particularly in the early phase of symptomatic patients. Sequen-
tial sampling of an individual patient allowed us tomonitor Ebola
viral load levels in venous and capillary blood samples during the
course of clinical illness (Table 3). This patient, suspected of hav-
ing EVD based on clinical symptoms, was admitted 1 day after
the onset of symptoms to the ETC. At the day of admission, lab-
oratory results were negative for EVD in both sample types. RT-
PCR testing was repeated 48 hours later and the patient tested
positive for Ebola RNA in the venous blood sample but remained
Ebola RNA negative in the capillary blood sample. On day 4,
both sample types tested EVD positive, with the venous blood
sample showing a higher viral load compared with the capillary
blood sample. On day 7, EVD-positive test results revealed sim-
ilar Ct values for capillary blood and venous blood, indicating
comparable viral load. These data indicate potential differences
in viremia between venous and capillary blood according to
time of disease onset. This might also explain the 2 additional
discordant results between venous blood and capillary blood
from day 2 and day 3 after onset of symptoms (Table 2, samples
7 and 19). Yet with low numbers of patients, further studies are
needed to compare the kinetics of viral load in venous and cap-
illary blood during the course of infection.
Table 1. Sensitivity and Speciﬁcity of Tests Performed on
Capillary Blood Specimens for the Diagnosis of Ebola Virus
Infection
Ebola Virus Detection
With Capillary Blood Samples
Ebola Virus Detection With
Standard Venous Blood Samples
Positive Negative Total
Positive 33 0 33
Negative 5 22 27
Total 38 22 60
Data are No. of samples. Results of Ebola virus detection in capillary finger-
stick samples were compared with samples obtained by venous blood punc-
ture using real-time reverse transcription polymerase chain reaction. The
sensitivity for detection of Ebola virus in capillary blood samples was
86.8% (95% confidence interval [CI], 71.9%–95.6%), the specificity was
100% (95% CI, 84.6%–100%), and the negative likelihood ratio was 0.13
(95% CI, .06–.30).
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For differential diagnostic, 52 out of 53 newly admitted pa-
tients were tested for malaria infections (Plasmodium species)
using an antigen-based rapid diagnostic test. Among the patients
who tested positive for EVD, 13 patients scored positive and 21
patients scored negative for malaria. For the patients who tested
EVD negative, 8 patients scored positive and 10 patients scored
Table 2. Comparison of Ebola Virus Load Between Venous Blood and Capillary Blood Samples Using Real-time Reverse Transcription
Polymerase Chain Reaction
No. of
Tested
Sample
Patient
No.
Day of
Sampling After
Symptom
Onset
EVD Detection in
Venous Blood (Ct
Value)
Semiquantitative
Viral Load
Resulta
EVD Detection in
Capillary Blood
(Ct Value)
Semiquantitative
Viral Load
Resultb
Ct Difference
Between Venous and
Capillary Blood
Samplesc
1 Patient 1 Day 1 Positive (22.47) +++ Positive (23.44) +++ +0.97
2 Patient 2 Day 1 Positive (15.49) +++ Positive (18.42) +++ +2.93
3 Patient 3 Day 1 Positive (25.59) ++ Positive (29.26) ++ +3.67
4 Patient 4 Day 2 Positive (20.31) +++ Positive (28.28) ++ +7.97
5 Patient 5 Day 2 Positive (21.38) +++ Positive (26.39) ++ +5.01
6 Patient 6 Day 2 Positive (26.03) ++ Positive (30.47) ++ +4.44
7 Patient 7 Day 2 Positive (30.48) ++ Negative (−) − NA
8 Patient 8 Day 3 Positive (16.42) +++ Positive (18.27) +++ +1.85
9 Patient 9 Day 3 Positive (18.10) +++ Positive (19.65) +++ +1.55
10 Patient 10 Day 3 Positive (28.08) ++ Positive (21.01) +++ −7.07
11 Patient 11 Day 3 Positive (23.39) +++ Positive (26.46) ++ +3.07
12 Patient 12 Day 3 Positive (18.77) +++ Positive (21.45) +++ +2.68
13 Patient 13 Day 3 Positive (23.94) +++ Positive (28.65) ++ +4.71
14 Patient 14 Day 3 Positive (24.32) +++ Positive (27.26) ++ +2.94
15 Patient 15 Day 3 Positive (22.64) +++ Positive (26.42) ++ +3.78
16 Patient 16 Day 3 Positive (20.74) +++ Positive (25.32) ++ +4.58
17 Patient 17 Day 3 Positive (19.48) +++ Positive (20.60) +++ +1.12
18 Patient 18 Day 3 Positive (26.17) ++ Negative (−) − NA
19 Patient 19 Day 3 Positive (27.03) ++ Negative (−) − NA
20 Patient 20 Day 4 Positive (15.31) +++ Positive (20.47) +++ +5.16
21 Patient 18 Day 4 Positive (22.23) +++ Positive (28.41) ++ +6.18
22 Patient 21 Day 4 Positive (20.19) +++ Positive (25.87) ++ +5.68
23 Patient 22 Day 4 Positive (21.46) +++ Positive (24.36) +++ +2.90
24 Patient 23 Day 4 Positive (17.71) +++ Positive (20.29) +++ +2.58
25 Patient 24 Day 5 Positive (19.01) +++ Positive (26.12) ++ +7.11
26 Patient 25 Day 5 Positive (21.12) +++ Positive (23.74) +++ +2.62
27 Patient 4 Day 5 Positive (21.02) +++ Positive (28.10) ++ +7.08
28 Patient 26 Day 5 Positive (21.99) +++ Positive (23.72) +++ +1.73
29 Patient 27 Day 6 Positive (17.06) +++ Positive (21.33) +++ +4.27
30 Patient 28 Day 6 Positive (21.84) +++ Positive (27.45) ++ +5.61
31 Patient 29 Day 6 Positive (22.04) +++ Positive (28.05) ++ +6.01
32 Patient 30 Day 6 Positive (21.74) +++ Positive (26.00) ++ +4.26
33 Patient 18 Day 7 Positive (16.00) +++ Positive (17.00) +++ +1.00
34 Patient 31 Day 9 Positive (25.04) ++ Positive (30.01) ++ +4.97
35 Patient 32 Day 15 Positive (31.77) ++ Negative (−) − NA
36 Patient 33 Day 17 Positive (17.04) +++ Positive (19.43) +++ +2.39
37 Patient 34 Day 18 Positive (24.35) +++ Positive (25.60) ++ +1.25
38 Patient 35 Not known Positive (30.61) ++ Negative (−) − NA
Abbreviations: Ct, cycle threshold; EVD, Ebola virus disease; NA, not applicable.
a Ct values are classified in subsequent categories of 0–24 (highly positive), 25–34 (positive), and 35–40 (weak positive) and correspond with +++, ++, and + results,
respectively.
b Negative real-time reverse transcription polymerase chain reaction result is indicated by “–.”
c For Ct differences, “+” indicates higher viral load in venous blood sample, whereas “–” indicates higher viral load in capillary blood sample.
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negative for malaria. Comparison of results between matched
capillary blood and venous blood samples and malaria coinfec-
tions showed that malaria coinfections had no inﬂuence on the
sensitive and speciﬁc detection of EVD when using capillary
blood samples (data not shown).
Due to the favorable location in Guéckédou with the European
Mobile Laboratory adjacent to the MSF ETC, blood samples col-
lected from patients, including the capillary blood specimens,
could be treated for laboratory diagnosis within 1 hour to a few
hours. However, in other settings, timely delay between specimen
collection and laboratory analysis might bemuch greater. In cases
where EVD diagnostics can not be performed within 24 hours
after sample collection, theWHO recommends a storage temper-
ature between 0°C and 5°C for sample specimens to maintain
sample preservation [24]. In a limited test, we addressed sample
stability under ﬁeld conditions and observed rapid sample degra-
dation when capillary blood swab samples were stored for >24
hours at room temperature compared with corresponding sam-
ples stored at 4°C, indicating an impact of storage conditions on
sensitive Ebola nucleic acid detection by RT-PCR using capillary
blood swab samples (data not shown).
DISCUSSION
Efﬁcient interruption of Ebola virus transmission chains critically
depends on reliable and rapid laboratory diagnosis of patients
suspected of having EVD. The laboratory results are needed to
conﬁrm suspected cases and to execute subsequent isolation
measures. The high numbers of patients with suspected EVD ad-
mitted to ETCs in the affected countries Liberia, Sierra Leone,
and Guinea often requires large-scale sampling of patients. A
major challenge is sampling of venous blood in patients with sus-
pected EVD, posing a serious risk to healthcare workers due to
accidental needlestick injuries [25]. The less invasive collection of
capillary blood samples could be an alternative approach,
strongly reducing the risk for medical personnel. In addition,
capillary blood samples might be useful for monitoring viral
load during the course of disease where repeated sampling by
venous puncture would be too much of a strain for severely suf-
fering EVD patients. The aim of this study was therefore to eval-
uate the feasibility of using capillary blood samples from
ﬁngertips for detection of Ebola virus and to compare the re-
sults with blood samples obtained by venipuncture. Analyzing
capillary blood specimens collected from 53 patients with sus-
pected EVD, we demonstrate for the ﬁrst time the applicability
of blood samples derived from ﬁngersticks for the detection of
EVD by RT-PCR.
As shown in Table 2, pairwise comparison of venous blood
samples and capillary blood samples revealed in general a
good correlation of test results for patients who were found to
be positive for EVD. Compared to venous blood samples, cap-
illary blood samples from ﬁngerpricks revealed a sensitivity of
86.8% (95% conﬁdence interval [CI], 71.9%–95.6%; 33/38 pa-
tients) and a speciﬁcity of 100% (95% CI, 84.6%–100%; 22/22
patients), respectively. Our ﬁndings thus support the use of cap-
illary blood samples as an alternative diagnostic specimen to ve-
nous blood samples in an outbreak situation.
Due to the observed 100% speciﬁcity of test results in our ﬁeld
study, we consider a positive EVD laboratory result from capillary
blood samples valid for reliable diagnostic evaluation. Capillary
blood sampling may therefore represent a suitable diagnostic ap-
proach for initial rapid screening of a large number of patients in
the midst of an outbreak, allowing accelerated EVD patient man-
agement and isolation measures. Suspected cases testing negative
for EVD using capillary blood samples should be additionally
tested using venous blood samples, the current gold standard
specimen for RT-PCR–based EVD diagnosis. Similarly, at pre-
sent, venous-derived blood is recommended for testing patients
during the convalescent phase to enhance decision making on
their discharge and reintroduction in the community.
Those cases when capillary blood samples were less sensitive
or tested negative compared with venous blood samples may re-
late to the stage of disease. At present, no information is avail-
able regarding Ebola viral load kinetics in capillary blood during
Table 3. Real-time Reverse Transcription Polymerase Chain Reaction Results From an Individual Patient in the Course of a Follow-up
Study During His Stay at the Ebola Treatment Center, Guéckédou, Guinea, August 2014
Day of Sampling After
Symptom Onset
EVD Detection in Venous
Blood (Ct Value)
Semiquantitative Viral
Load Resulta
EVD Detection in Capillary
Blood (Ct Value)
Semiquantitative Viral
Load Result
Day 1 Negative (−) − Negative (−) −
Day 3 Positive (26.17) ++ Negative (−) −
Day 4 Positive (22.23) +++ Positive (28.41) ++
Day 7 Positive (16.00) +++ Positive (17.00) +++
Abbreviations: Ct, cycle threshold; EVD, Ebola virus disease.
a Ct values are classified in subsequent categories of 0–24 (highly positive), 25–34 (positive), and 35–40 (weak positive) and correspond with +++, ++, and + results,
respectively. Negative real-time reverse transcription polymerase chain reaction result is indicated by “−.”
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the course of infection. Future studies should address the vire-
mia in the capillary blood according to the stage of clinical ill-
ness to ensure valid interpretation of diagnostic results.
Alternatively, the differences in viral load between the 2
specimen types might be due to inherent sampling and collec-
tion procedures (Supplementary Figure 2). Although introduc-
ing identical blood volumes (eg, from whole blood vacutainers
into sample preparation) is easy to achieve, adsorption and de-
sorption of capillary blood from swab ﬁngerpricks might vary,
thus explaining the observed differences in Ct values. Further
studies should address standardization of collection procedures
and sampling volumes for the swab approach.
Finally, in this study we compared EDTA-anticoagulated
blood collected by venipuncture and capillary blood samples
that were deposited onto viscose swab devices, exhibiting no an-
ticoagulation activity. Protective effects of EDTA on stability of
pathogen-derived RNA in blood samples have been reported
[26]. Despite this fact, we haven chosen these swab devices for
our comparison study, as the European Mobile Laboratory units
in Guéckédou, Guinea, and Foya, Liberia, received a consider-
able number of capillary blood samples absorbed onto viscose
swabs as a diagnostic sample specimen from both infants and
adults for EVD testing (unpublished observation). Although
these types of swabs are routinely used for sensitive detection
of Ebola virus in oral ﬂuids in the current EVD outbreak in
West Africa [27, 28], at present very little is known about the
stability of Ebola virus RNA or potential degradation effects
in capillary blood samples absorbed onto swabs. Rapid RNA
degradation might result in lower detection sensitivity or even
render a test falsely negative. Thus, the value of swabs as a col-
lection and storage device for capillary blood samples for diag-
nostic purposes needs to be further evaluated and compared
with capillary blood samples collected into a microcollection
container that has EDTA as an anticoagulant.
Capillary blood sampling offers some advantages over blood
sampling by venipuncture. Sampling can be done by medical
health personnel other than experienced and trained phlebo-
tomists. Furthermore, for patient convenience and in some cir-
cumstances for cultural reasons and religious beliefs, this
procedure may be more acceptable than venous blood draw.
Thus, the less invasive collection of samples eliminates the anx-
iety associated with venipuncture and may lead to higher accep-
tance of blood testing in settings where cultural traditions
otherwise might interfere with effective outbreak management.
Moreover, capillary blood collection is the preferred method of
blood specimen collection for newborns and infants. These
practical reasons might outbalance the higher sensitivity ob-
served in some cases for venous blood analysis, particularly in
the critical situation of an outbreak.
Reliable detection and laboratory conﬁrmation of Ebola virus
is key to successfully controlling the current EVD outbreak in
West Africa. The WHO has identiﬁed an ongoing need to de-
velop sensitive and speciﬁc tests for diagnosis of EVD using ac-
cessible point-of-care (POC) technologies, including POC
ﬁngerstick tests that are capable of providing early diagnosis
of EVD and Ebola viral load measurement. Our report is the
ﬁrst study that compares the sensitivity of RT-PCR–based
EVD tests on capillary vs venous blood samples. Although a
more extensive evaluation of capillary blood specimens under
ﬁeld conditions is still needed, our results point toward the
use of capillary blood samples as an appropriate collection
specimen for sensitive and speciﬁc diagnosis of EVD. In conclu-
sion, this study demonstrates the value of capillary ﬁngerstick
blood as a clinical sample specimen for virologic diagnosis of
Ebola virus infection during an outbreak emergency.
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